Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT01208649 on ClinicalTrials.gov · last registry update 2010-09-24

A small phase 4 — 13 participants, against a typical 75. The sponsor logged completion for September 2010. Primary outcome, as filed: histological activity of NASH (steatosis, necroinflammation, ballooning). exenatide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Ruhr University of Bochum
Sponsor type: Other
Enrollment: 13
Started: 2008-07
Primary completion: 2010-09 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

histological activity of NASH (steatosis, necroinflammation, ballooning)

Conditions studied

Nonalcoholic Fatty Liver Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.